Tyratech (DI) Share Discussion Threads

[h2owater] 20/2/2014 08:33

TyraTech's repellent has none of these issues and Jactel is in talks with Amazon and other large retailers about putting it on the shelves and online. The company has also secured a partner – Swiss drugs giant Novartis – to distribute its animal insect repellent. Looks like market has factored in issue of equity!Too much happening with TyraTech this year.

[dellers01] 19/2/2014 23:11

Baxter, look at their website...........

[baxter99] 19/2/2014 20:51

I am also curious to know why and American company is listed under two companies in the UK but nowhere else, not even the USA, or am i misinformed?

[nobbygnome] 19/2/2014 19:17

>> baxter

I give up..........

I explained it all last week. You keep on believing what you want to believe........

Nobby

[baxter99] 19/2/2014 18:59

I have looked - it still says homeopathic on the box and that's what people will see. Nothing wrong with that - there's money to be made from homeopathy. I don't know why they do not state the active ingredients on the box instead - unless they think the public prefer homeopathic remedies. Seems odd to state it's homeopathic when it might not be - does that not contravene goods description or their equivalent in the states.

[bozzy_s] 19/2/2014 18:59

Short term there are more important things than homeopathic labels to worry about. The 5p placing shares hitting the market after a huge spike in TYRU's price.

Absolutely gutted I couldn't open a short at 18/19/20/21p as hoped. TYRU was always going to come crashing down because of the premium vs TYR. And it was so obviously short-term traders who caused the spike, and by definition would sell within days. Any long term buyers would've bought the cheaper TYR and waited for them to convert to TYRU in due course.

Such an obvious and predictable situation which unfortunately I couldn't capitalise on. Well done to everyone who managed to sell TYRU and buy TYR.

Hoping TYRU surge up to 18/19/20p as traders desperately try to cause a spike again. Then I'll try, once more, to short to around 10p, which seems a reasonable target given the 5p placing price, and the 7p price-tag before being tipped.

[dassaco] 19/2/2014 18:22

It is for sale labelled as homeopathic as the label states.
However it is not the same as other homeopathic treatments, is protected by patents and has taken many years to develop.
Have a look at the Tyratech website and past posts on the TYR message board and it is explained or talk to the company.

[baxter99] 19/2/2014 17:02

To re-iterate. Vamousse is a homeopathic remedy (as stated on the packaging)

[h2owater] 19/2/2014 16:45

To re-iterate!!!

MIDAS SHARE TIPS: Get a flying start if you're itching to share in £430m head lice market with TyraTech

By JOANNE HART, FINANCIAL MAIL ON SUNDAY

PUBLISHED: 22:01, 8 February 2014 | UPDATED: 10:36, 10 February 2014

Target: Vamousse is safer than rival products and will be sold by Walmart, says boss Alan Reade, left

Irritating and unpleasant, head lice infestations are also difficult to eliminate. In the 1970s, about 5 per cent of children suffered from head lice during their school life. Today, more than 30 per cent are affected.

TyraTech has a revolutionary new treatment that kills all lice and their eggs. Pesticide-free, TyraTech's Vamousse products use oils from plants and
vegetables. The US firm's shares are just 61⁄2p but should rise significantly as the Vamousse range is rolled out and other ground-breaking products come to market.

Last month, TyraTech chairman Alan Reade revealed that giant US supermarket chain Walmart will start stocking Vamousse head lice treatment and preventative shampoo from the start of April.

The products are already on sale at about 2,500 independent pharmacies in the US but talks are being held with groups that represent thousands more.

In the UK too, Reade and his chief executive, Bruno Jactel, are negotiating with several top retailers and deals should be announced within weeks.

The global head lice market is worth more than £430 million a year and TyraTech should capture a significant percentage of it over the next five years. Lice have developed a resistance to many treatments, which can also have side effects, such as scalp irritation and headaches. As a natural product, Vamousse is safer and it has been approved by the US Food and Drug Administration, one of the toughest pharmaceutical watchdogs.

But head lice treatment is just one weapon in TyraTech's armoury. The firm has also developed natural insect repellents for humans and animals, a market worth almost £1.5 billion a year globally.

Most insect repellents for people rely on a compound known as DEET, which was developed about 60 years ago. Some repellents contain just 5 per cent of DEET and are relatively ineffective. These days, however, stronger products are on the market, containing up to 50 per cent.

These do stave off insects, but can have unpleasant side effects – they are not supposed to be used on children, they do not work well with sun-block and they can even melt plastic, such as watch straps.

TyraTech's repellent has none of these issues and Jactel is in talks with Amazon and other large retailers about putting it on the shelves and online. The company has also secured a partner – Swiss drugs giant Novartis – to distribute its animal insect repellent.

Insects are a big problem on farms, especially if animals are kept in barns. Spraying chemical-based insecticide in such spaces can harm the livestock, affect workers and infect the food chain. Certain insects have also become immune to them.

TyraTech's products are safe and effective and Novartis is scheduled to start selling them this year.

TyraTech acquired its technology from Vanderbilt University in Nashville, and the company is still based in the US.

Having joined AIM in 2007, it spent several years thinking more about research than commercial success, but Reade became chairman in 2010 and last year, he brought in Jactel.

Reade formerly chaired Merial, a £1.5 billion animal health company, which makes the pet flea product Frontline.

Jactel, who was originally a vet, was chief marketing officer at Merial and helped make Frontline the most successful consumer brand in the world for pets.

Since arriving at TyraTech, Jactel has focused the business on three main areas – head lice treatment, insect repellent for humans and repellent for farm animals. He has also concentrated on the US. Over the next few years, however, the group is expected to expand into Britain and the rest of Europe, as well as Asia and South America.

It will also extend its product range, as there is clear potential for the insecticide products to be used on pets. Jactel is even talking about embedding insecticide into plastic bags or rubbish bins to prevent the spread of disease.

Midas verdict: As a small business, TyraTech is a riskier investment than some. But it is expected to move into profit next year and grow quickly thereafter. Reade and Jactel are used to leading large, international companies and there are high hopes that TyraTech will either become a major player or be acquired by one. Adventurous investors should reap the benefits either way. Buy.


Read more:

[michaelsadvfn] 18/2/2014 11:56

Hard to say where this will settle but at 20p when the placing shares hit the market Tyratech would have a market cap of over £40m with first profits not due until 2015.

Consolidation until the next news.

[deepvalueinvestor] 18/2/2014 11:47

Did you miss out? If you want to buy then perhaps get a good broker and buy tyr at 13p?! Predictable that tyru down more than tyr today as some investors switch.

[msarwar014] 18/2/2014 11:31

Selling will accelerate once US opens IMo

[msarwar014] 18/2/2014 10:33

IMO will retrace back to approx. 12p 38% fib level

[deepvalueinvestor] 17/2/2014 21:43

I would give up Nobby! The important thing is that idiots are still keeping the price of tyru high when I convert in April.

[nobbygnome] 17/2/2014 20:30

The market cap is dependent on the number of each type of share. I don't know how many times we have to say this but..... the share classes are of equal value and the TYRs can be converted directly into TYRUs!!!

Some people just don't listen..........

Nobby

[modform] 17/2/2014 19:53

Buzzy, I think the market cap of xxm consists of tyr plus tyru. Tyru has bigger market cap than tyr, about 30% bigger, and hence the higher share price The market is more clever than we think. I am not a holder here, lack of funds unfortunately.

[dellers01] 17/2/2014 16:01

They've just realised,

[dellers01] 17/2/2014 14:22

Because right now youre getting a higher increase in profit bozzy

[andrbea] 17/2/2014 13:56

sorry if posted before:

[bozzy_s] 17/2/2014 13:34

Still no quote to sell TYRU or buy TYR on spreadbet. I'd best leave this one alone, it's driving me nuts! Can't for the life of me understand why people are now paying a 50% premium for the same company shares!!

[deepvalueinvestor] 16/2/2014 09:37

Bozzy, it is indeed amazing but it is the market makers fault as they are trying to keep tyr down by not allowing the large holders to buy in size after selling tyru. I managed to do most of my switches at 9.3p to 7.5p but others are struggling to sell at 18p and buy back at 13p for obvious reasons. However, smaller investors selling 35k and buying 25k will be ok.

I look forward to a good week on tyr even if tyru keeps slipping back as it did late on Friday.

I must admit that I have seen nothing like this in 15 years of investing. Quite bizarre.

[bozzy_s] 16/2/2014 02:11

90 someuwin - please read above, TYR and TYRU are the same! Same company. Same value. Except some very short term traders have been buying TYRU at a stupid, mindless, thoughtless idiotic premium. It beggars belief.

It has to be short term traders, as any investor with an IQ above 50 would buy TYR, and wait for them to be converted to TYRU sometime in the next year.

Will desperately try to spreadbet down TYRU / up TYR Monday, assuming the silly price differential remains.

[someuwin] 16/2/2014 00:04

I prefer TYRU to TYR.

[dellers01] 15/2/2014 22:22

Oh, ok if they don't move at the same rate it is understandable.

[deepvalueinvestor] 15/2/2014 21:50

Well they were at the same price a few weeks ago so when I convert 1000 shares at 13p into 1000 shares at 18p, I'm clearly happier! This is why I no longer hold tyru. The problem is caused by smaller brokers and HL not dealing in tyr so their clients have to buy the expensive share class if they want exposure.